This is a deliberate strategic decision, not an oversight, and understanding why illuminates the science and business of oral peptide delivery
But once that appetite shift settles in, the real conversation begins
Suda N, Cendejas Hernandez J, Poulton J, Jones JP, Konsoula Z, Smith C, et al
Without this integration of biomarkers, it will remain difficult to distinguish symptomatic effects from true disease modification
Moreover, determining the precise timing for treatment, especially the critical time point for reperfusion postconditioning, remains a major challenge that continues to perplex researchers [33]
Why are GLP-1 agonists so groundbreaking